Skip to main
  1. Stocks
  2. Corcept Therapeutics
  3. Forecast
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

Corcept Therapeutics is viewed positively because 3Q26 results showed clear commercial momentum, with diluted EPS of $1.01 on revenue of $340.5M versus estimates of $0.79 and $336.4M, while management kept 2026 revenue guidance at $1.1B-$1.2B, implying about 51% growth at the midpoint. Lifyorli is scaling rapidly, reaching $91.4M in its second full quarter with over 2,300 patients started and more than 1,700 prescribers, while Korlym still rose 19% to $249.1M despite generic competition, suggesting the franchise can absorb pricing pressure through volume. The outlook is further supported by relacorilant’s advancing regulatory path, including a positive CHMP opinion on September 18, 2026 and a potential resubmission for Cushing’s syndrome, which could add another catalyst to a pipeline already aimed at multiple high-value indications.

Bears say

Corcept Therapeutics is facing a clouded international growth outlook because Most Favored Nation pricing makes the launch case beyond the U.S. difficult to underwrite, especially in Europe. The company has not yet committed to a European launch strategy, and the author excludes non-U.S. Lifyorli revenues from valuation because MFN pricing may pressure pricing, uptake, and economics. This raises reliance on the U.S. market alone, limiting near-term upside even though peer launches have shown an ex-U.S. market can exist, but under more favorable timing than the May 12, 2025 MFN announcement.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction

Get the latest Corcept Therapeutics (CORT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Corcept Therapeutics (CORT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $124.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $124.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction

Get the latest Corcept Therapeutics (CORT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Corcept Therapeutics (CORT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CORT stock data and trends